Twist Bioscience Corporation (TWST)
NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TWST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.32B
- EPS (TTM)
- -$2.42
- Dividend yield
- None
- 52-week range
- 23.30 – 219.71
- Day range
- 152.50 – 167.29
- Volume / Avg
- 5.89M / 1.93M
- Beta
- —
- Shares outstanding
- 66.30M
52-week range
TWST stock today
Shares of Twist Bioscience (TWST) finished lower on Oct 7 at $155.65, a drop of 6.78% or $11.32 per share, versus the S&P 500's 0.22% decline. Volume was 3.1x the average at 5.89M shares, a sign of unusually heavy trading. At this level, TWST sits in the middle of its 52-week range of $23.30 to $219.71: 29.2% below the high, set on Oct 6, 2026 and 568.0% above the low.
TWST is up 390.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 400.2%. Twist Bioscience has posted a net loss over the last twelve months (EPS of -$2.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Twist Bioscience
Company profileTwist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Emily Marine Leproust Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 979
- IPO year
- 2018
- Website
- twistbioscience.com
Financial highlights
Full financialsIn fiscal 2025, Twist Bioscience generated $376.6 million in revenue, up 20.3% from fiscal 2024, its 8th consecutive year of revenue growth. Twist Bioscience reported a net loss of $77.7 million, compared with a loss of $208.7 million a year earlier. Gross margin was 50.7% (up from 42.6%) and operating margin -36.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $376.57M | $312.97M | $245.11M | $203.56M | $132.33M |
| Growth | +20.32% | +27.69% | +20.41% | +53.83% | +46.87% |
| Net income | $-77.67M | $-208.73M | $-204.62M | $-217.86M | $-152.10M |
| EPS (diluted) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$133.75-14.07%
- Strong buy 2
- Buy 7
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2026)
- Aug 3, 2026
- EPS actual vs est.
- $-0.56 vs —
TWST news
All TWST newsTwist Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs TWST |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs TWST |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs TWST |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs TWST |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs TWST |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs TWST |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs TWST |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs TWST |
Indexes, lists and sector
Twist Bioscience stock FAQ
What is Twist Bioscience's stock price today?
TWST last traded at $155.65 as of Oct 7, 4:00 PM EDT, down 6.78% on the day. Prices are delayed at least 15 minutes.
Who is Twist Bioscience's CEO?
Dr. Emily Marine Leproust Ph.D. is the chief executive officer of Twist Bioscience Corporation, which has about 979 employees.
What is the TWST 52-week high?
The 52-week high for TWST is $219.71 and the 52-week low is $23.30. The stock is currently 29.2% below its high.